Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:41 UTC |
---|
HMDB ID | HMDB0014635 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Fosinopril |
---|
Description | Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. |
---|
Structure | CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1 |
---|
Synonyms | Value | Source |
---|
(2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | ChEBI | (2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid | ChEBI | (S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid | ChEBI | (2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate | Generator | (2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylate | Generator | (S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylate | Generator | Fosinopril sodium | HMDB | Monopril | HMDB | Newace | HMDB | Squibb brand OF fosinopril sodium | HMDB | Staril | HMDB | Bristol-myers squibb brand OF fosinopril sodium | HMDB | Dynacil | HMDB | Fosenopril | HMDB | Fosinopril, (1(s*(r*)),2 alpha,4 beta)-isomer | HMDB | Fosinopril, (1(s*(s*)),2 alpha,4 beta)-isomer | HMDB | Fositens | HMDB | Sanol brand OF fosinopril sodium | HMDB | Sodium, fosinopril | HMDB | Tensocardil | HMDB | Bristol myers squibb brand OF fosinopril sodium | HMDB | Ferrer brand OF fosinopril sodium | HMDB | Fosinil | HMDB | Fosinorm | HMDB | Schwarz brand OF fosinopril sodium | HMDB | Esteve brand OF fosinopril sodium | HMDB | Fosinopril, (1(s*(r*)),2 alpha,4 alpha)-(D-pro)-isomer | HMDB | Fozitec | HMDB | Hiperlex | HMDB | Merck lipha santé brand OF fosinopril | HMDB | Tenso stop | HMDB |
|
---|
Chemical Formula | C30H46NO7P |
---|
Average Molecular Weight | 563.6625 |
---|
Monoisotopic Molecular Weight | 563.301189343 |
---|
IUPAC Name | (2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid |
---|
Traditional Name | fosinopril |
---|
CAS Registry Number | 98048-97-6 |
---|
SMILES | CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |
---|
InChI Identifier | InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1 |
---|
InChI Key | BIDNLKIUORFRQP-FKDWWROVSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Proline and derivatives |
---|
Alternative Parents | |
---|
Substituents | - N-acyl-alpha-amino acid
- N-acyl-alpha amino acid or derivatives
- N-acyl-l-alpha-amino acid
- Proline or derivatives
- N-acylpyrrolidine
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- Dicarboxylic acid or derivatives
- Monocyclic benzene moiety
- Benzenoid
- Tertiary carboxylic acid amide
- Pyrrolidine
- Carboxylic acid ester
- Carboxamide group
- Phosphinic acid ester
- Organoheterocyclic compound
- Carboxylic acid
- Azacycle
- Organophosphorus compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organic oxide
- Organopnictogen compound
- Hydrocarbon derivative
- Carbonyl group
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 149 - 153 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.001 g/L | Not Available | LogP | 6.3 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Fosinopril GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-9211610000-94f1646db6bff331382d | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fosinopril GC-MS (1 TMS) - 70eV, Positive | splash10-052f-9011161000-d47389b6092a1bdbc108 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fosinopril GC-MS ("Fosinopril,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fosinopril GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , negative-QTOF | splash10-014i-0000900000-f61a6a8a62cc0c92102b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , negative-QTOF | splash10-014i-0000900000-ed280398ec57e4a02dce | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , negative-QTOF | splash10-00di-0090300000-4e1c300644a39a64aefe | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , negative-QTOF | splash10-00di-0090000000-85f8c80f83290feea35c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , negative-QTOF | splash10-00di-0090000000-e28a43e299ff58e3a6bc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , negative-QTOF | splash10-014i-0010900000-a142ed389f6652d197f1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , negative-QTOF | splash10-00di-1090000000-833fa43a37b31e08737c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , negative-QTOF | splash10-00di-1090000000-cda46913f10b57e39204 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , negative-QTOF | splash10-00di-2290000000-8627963d14d5d091e338 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , negative-QTOF | splash10-0229-7890000000-a5186e8ef5fa038d0a91 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , negative-QTOF | splash10-03k9-9720000000-ff0242177e3d4ef6c38a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , positive-QTOF | splash10-000f-0000900000-a2e65cd39ca7266f3a02 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , positive-QTOF | splash10-000i-0000900000-0eee13fe1a605e98c985 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , positive-QTOF | splash10-00ku-0105900000-1253dd1cea86dcfde7f6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , positive-QTOF | splash10-0udl-0908200000-59ff4955c6e6b2d36435 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QTOF , positive-QTOF | splash10-0udi-0901000000-e2b0d1bb8bfd4d6f7595 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , positive-QTOF | splash10-000i-0000900000-f625a00c8eb75cbf317d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , positive-QTOF | splash10-0f6x-0409200000-5a18b8096c457898aa5f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fosinopril LC-ESI-QFT , positive-QTOF | splash10-0udi-0900000000-28e69824d7a0442561b6 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fosinopril 10V, Positive-QTOF | splash10-052g-8501940000-1921bd0fb11f89e7ac6d | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fosinopril 20V, Positive-QTOF | splash10-0a4l-9742100000-b1fe493a8ecd28a1063b | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fosinopril 40V, Positive-QTOF | splash10-0006-9300100000-2565c33f04881158cfa2 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fosinopril 10V, Negative-QTOF | splash10-0a4i-9001350000-645f2ba1f7eb05f66e9c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fosinopril 20V, Negative-QTOF | splash10-0adj-8956210000-4bf1693483e47cacee67 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fosinopril 40V, Negative-QTOF | splash10-001a-1690000000-5349ec5626e3dd64f38d | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|
General References | - Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095 ]
- David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791 ]
|
---|